Overview

A Study to Assess Injection Comfort of Two Formulations of ATX-101

Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
To assess the safety and injection comfort of ATX-101-BA versus ATX-101-BA-free immediately following injection and at regular intervals up to 24-hours post-injection following subcutaneous administration into the submental area.
Phase:
Phase 1
Details
Lead Sponsor:
Kythera Biopharmaceuticals